Insiders Relmada Therapeutics, Inc.

Equities

RLMD

US75955J4022

Market Closed - Nasdaq Other stock markets 01:00:00 2024-07-03 pm EDT			5-day change	1st Jan Change
3.01 ^USD	+0.67%		+0.67%	-27.29%

Jul. 01	Relmada Therapeutics, Inc.(NasdaqGS:RLMD) added to Russell Microcap Growth Index	CI
Jul. 01	Relmada Therapeutics, Inc.(NasdaqGS:RLMD) added to Russell 3000E Growth Index	CI

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Relmada Says Chief Medical Officer Leaving; Names Senior Clinical Development Advisor	Jan. 04	MT
Relmada Therapeutics, Inc. Announces Resignation of Cedric O?Gorman as Chief Medical Officer	Jan. 03	CI
Relmada Therapeutics, Inc. Announces Eric Schmidt to Resign from the Board, Chairman of the Audit Committee of the Board and as A Member of the Corporate Governance and Nominating Committee of the Board	23-09-06	CI
Relmada Therapeutics, Inc. Appoints Fabiana Fedeli to Board of Directors	23-01-12	CI
Relmada Therapeutics, Inc. Appoints Cedric O'Gorman MD as Chief Medical Officer	23-01-09	CI
Nurosene Health Names Chief Innovation and Regulatory Officer	22-07-22	MT
Relmada Therapeutics, Inc. Appoints John Hixon as Head of Commercial	22-07-21	CI
Insider Trends: Insider 90-Day Selling Trend Extended at Relmada Therapeutics	21-07-16	MT
Insider Trends: Insider Prolongs 90-Day Selling Trend at Relmada Therapeutics	21-06-02	MT
Insider Trends: Insider Prolongs Selling Trend at Relmada Therapeutics	21-05-05	MT
Insider Trends: Relmada Therapeutics Sees 90 Days of Insider Buying Trend Interrupting with Share Sale	21-04-05	MT
Insider Trends: 90-Day Insider Selling Trend Extended at Relmada Therapeutics	21-02-02	MT
Relmada Therapeutics, Inc. Announces Resignation of Thomas Wessel as Executive Vice President and Head of Research and Development	21-01-05	CI
Relmada Therapeutics Announces Appointments of New Executive	20-10-27	CI
Relmada Therapeutics Appoints Molly Harper as Executive Vice President of Operations	20-05-26	CI
Relmada Therapeutics, Inc. Appoints Marc de Somer, Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety	20-03-31	CI
Relmada Therapeutics, Inc. Announces Management Changes	20-03-09	CI
Relmada Therapeutics, Inc. Announces Management Changes	20-01-10	CI
Relmada Therapeutics, Inc. Announces Management Changes	19-12-20	CI
Relmada Therapeutics, Inc. Appoints Charles S. Ence, as Chief Financial Officer	19-07-29	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Insiders Relmada Therapeutics, Inc.

Equities

RLMD

US75955J4022

Insiders

Filters